Symbols / SLXN
SLXN Chart
About
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 4.69M |
| Enterprise Value | -2.53M | Income | -9.25M | Sales | — |
| Book/sh | 2.23 | Cash/sh | 2.96 | Dividend Yield | — |
| Payout | 0.00% | Employees | 11 | IPO | — |
| P/E | 0.00 | Forward P/E | -2.34 | PEG | — |
| P/S | — | P/B | 0.67 | P/C | — |
| EV/EBITDA | 0.28 | EV/Sales | — | Quick Ratio | 3.32 |
| Current Ratio | 3.97 | Debt/Eq | 29.02 | LT Debt/Eq | — |
| EPS (ttm) | 349.09 | EPS next Y | -0.64 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-12 09:00 | ROA | -77.60% |
| ROE | -7.71% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 3.13M |
| Shs Float | 3.00M | Short Float | 1.49% | Short Ratio | 0.80 |
| Short Interest | — | 52W High | 26.70 | 52W Low | 1.45 |
| Beta | -0.04 | Avg Volume | 50.51K | Volume | 4.59K |
| Target Price | $9.00 | Recom | None | Prev Close | $1.42 |
| Price | $1.50 | Change | 5.63% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$9.00
Mean price target
2. Current target
$1.55
Latest analyst target
3. DCF / Fair value
$-40.95
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.55
Low
$6.00
High
$12.00
Mean
$9.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-15 | init | Litchfield Hills | — → Buy | $6 |
| 2025-03-20 | main | Maxim Group | Buy → Buy | $5 |
| 2024-11-01 | init | Maxim Group | — → Buy | $1 |
- $6M Capital Raise: Clinical-Stage RNAi Cancer Biotech Silexion Prices Share & Warrant Offering at $4.00 - Stock Titan hu, 11 Sep 2025 07
- Silexion stock falls after receiving German regulatory feedback - Investing.com ue, 02 Dec 2025 08
- Liquidity Mapping Around (SLXN) Price Events - Stock Traders Daily ue, 10 Feb 2026 08
- Silexion Therapeutics Announces 1-for-15 Reverse Share Split - Yahoo Finance Wed, 16 Jul 2025 07
- Why SLXN stock is seen as undervalued - Quarterly Earnings Report & Free Community Consensus Stock Picks - mfd.ru Sat, 14 Feb 2026 03
- 97% Cancer Inhibition: Silexion's RNAi Therapy Shows Promise as Company Regains Nasdaq Status - Stock Titan hu, 25 Sep 2025 07
- Silexion Therapeutics Reveals Positive Preclinical Data for SIL204 - TipRanks hu, 11 Sep 2025 07
- Silexion stock jumps after toxicology studies show no systemic toxicity - Investing.com ue, 25 Nov 2025 08
- Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit - Yahoo Finance Wed, 21 Jan 2026 08
- SLXN Stock Price and Chart — NASDAQ:SLXN - TradingView Fri, 16 Aug 2024 14
- Silexion Therapeutics Gains Positive Feedback for SIL204 Trial - TipRanks ue, 02 Dec 2025 08
- Silexion stock soars 400% after positive pancreatic cancer drug data - Investing.com hu, 11 Sep 2025 07
- Revolutionary KRAS Cancer Treatment: Silexion Expands Development Strategy for SIL204 - Stock Titan Fri, 21 Mar 2025 07
- Silexion Therapeutics stock falls after warrant exercise deal - Investing.com Fri, 01 Aug 2025 07
- SLXN - Silexion Therapeutics Corp Latest Stock News & Market Updates - Stock Titan hu, 15 Aug 2024 20
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 450000 | 1800000 | — | Stock Award(Grant) at price 4.00 per share. | LEVIN ILAN | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-09-15 00:00:00 | I |
| 1 | 794 | — | — | Stock Award(Grant) at price 0.00 per share. | ALON RUTH | Director | — | 2025-02-07 00:00:00 | D |
| 2 | 1587 | — | — | Stock Award(Grant) at price 0.00 per share. | LUSHI AVNER | Director | — | 2025-02-07 00:00:00 | I |
| 3 | 794 | — | — | Stock Award(Grant) at price 0.00 per share. | ABRAMOV DROR YOSEF | Director | — | 2025-02-07 00:00:00 | D |
| 4 | 1587 | — | — | Stock Award(Grant) at price 0.00 per share. | NOY SHLOMO | Director | — | 2025-02-07 00:00:00 | I |
| 5 | 661 | — | — | Stock Award(Grant) at price 0.00 per share. | PELED AMNON PH.D. | Director | — | 2025-02-07 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| TaxEffectOfUnusualItems | -56.81K | -104.19K | -149.50K |
| TaxRateForCalcs | 0.23 | 0.23 | 0.23 |
| NormalizedEBITDA | -16.23M | -4.57M | -3.15M |
| TotalUnusualItems | -247.00K | -453.00K | -650.00K |
| TotalUnusualItemsExcludingGoodwill | -247.00K | -453.00K | -650.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -16.44M | -4.94M | -3.21M |
| ReconciledDepreciation | 25.00K | 45.00K | 57.00K |
| EBITDA | -16.48M | -5.03M | -3.80M |
| EBIT | -16.50M | -5.07M | -3.86M |
| NetInterestIncome | -4.84M | 144.00K | 29.00K |
| InterestExpense | 7.00K | 6.00K | |
| InterestIncome | 1.00K | 153.00K | 114.00K |
| NormalizedIncome | -16.25M | -4.59M | -2.71M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -16.44M | -4.94M | -3.21M |
| TotalExpenses | 12.57M | 4.68M | 3.86M |
| RentExpenseSupplemental | 89.00K | 86.00K | 71.00K |
| TotalOperatingIncomeAsReported | -12.57M | -4.68M | -3.86M |
| DilutedAverageShares | 41.59K | 60.38K | 60.38K |
| BasicAverageShares | 41.59K | 60.38K | 60.38K |
| DilutedEPS | -395.40 | -81.85 | -53.24 |
| BasicEPS | -395.40 | -81.85 | -53.24 |
| DilutedNIAvailtoComStockholders | -16.44M | -4.94M | -3.21M |
| NetIncomeCommonStockholders | -16.44M | -4.94M | -3.21M |
| NetIncome | -16.44M | -4.94M | -3.21M |
| MinorityInterests | 76.00K | 166.00K | 273.00K |
| NetIncomeIncludingNoncontrollingInterests | -16.52M | -5.11M | -3.49M |
| NetIncomeContinuousOperations | -16.52M | -5.11M | -3.49M |
| TaxProvision | 10.00K | 32.00K | 24.00K |
| PretaxIncome | -16.51M | -5.08M | -3.46M |
| OtherIncomeExpense | 903.00K | -539.00K | 367.00K |
| OtherNonOperatingIncomeExpenses | 1.15M | -86.00K | 1.02M |
| GainOnSaleOfSecurity | -247.00K | -453.00K | -650.00K |
| NetNonOperatingInterestIncomeExpense | -4.84M | 144.00K | 29.00K |
| TotalOtherFinanceCost | 4.83M | 3.00K | 85.00K |
| InterestExpenseNonOperating | 7.00K | 6.00K | |
| InterestIncomeNonOperating | 1.00K | 153.00K | 114.00K |
| OperatingIncome | -12.57M | -4.68M | -3.86M |
| OperatingExpense | 12.57M | 4.68M | 3.86M |
| DepreciationAmortizationDepletionIncomeStatement | 25.00K | 45.00K | 57.00K |
| DepreciationAndAmortizationInIncomeStatement | 25.00K | 45.00K | 57.00K |
| DepreciationIncomeStatement | 25.00K | 45.00K | 57.00K |
| ResearchAndDevelopment | 5.82M | 3.71M | 3.23M |
| SellingGeneralAndAdministration | 6.73M | 928.00K | 577.00K |
| GeneralAndAdministrativeExpense | 6.73M | 928.00K | 577.00K |
| OtherGandA | 2.05M | 486.00K | 287.00K |
| RentAndLandingFees | 89.00K | 86.00K | 71.00K |
| SalariesAndWages | 4.59M | 356.00K | 219.00K |
| TotalRevenue | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | ||
|---|---|---|---|
| TreasurySharesNumber | 28.00 | ||
| OrdinarySharesNumber | 123.25K | 60.38K | 60.38K |
| ShareIssued | 123.28K | 60.38K | 60.38K |
| NetDebt | 2.78M | ||
| TotalDebt | 4.49M | 171.00K | 271.00K |
| TangibleBookValue | -3.99M | -15.48M | -10.66M |
| InvestedCapital | -24.00K | -15.48M | -10.66M |
| WorkingCapital | -1.27M | 2.78M | 7.23M |
| NetTangibleAssets | -3.99M | -15.48M | -10.66M |
| CapitalLeaseObligations | 526.00K | 171.00K | 271.00K |
| CommonStockEquity | -3.99M | -15.48M | -10.66M |
| TotalCapitalization | -1.03M | -15.48M | -10.66M |
| TotalEquityGrossMinorityInterest | -3.99M | -12.06M | -7.08M |
| MinorityInterest | 0.00 | 3.42M | 3.59M |
| StockholdersEquity | -3.99M | -15.48M | -10.66M |
| RetainedEarnings | -43.25M | -26.81M | -21.87M |
| AdditionalPaidInCapital | 39.26M | 11.34M | 11.20M |
| CapitalStock | 2.00K | 0.00 | 1.00K |
| CommonStock | 2.00K | 0.00 | 1.00K |
| TotalLiabilitiesNetMinorityInterest | 6.85M | 17.31M | 16.41M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 3.33M | 15.12M | 14.80M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 15.06M | 14.65M |
| LongTermDebtAndCapitalLeaseObligation | 3.33M | 59.00K | 156.00K |
| LongTermCapitalLeaseObligation | 368.00K | 59.00K | 156.00K |
| LongTermDebt | 2.96M | ||
| CurrentLiabilities | 3.52M | 2.20M | 1.61M |
| OtherCurrentLiabilities | 2.00K | 200.00K | 3.00K |
| CurrentDebtAndCapitalLeaseObligation | 1.16M | 112.00K | 115.00K |
| CurrentCapitalLeaseObligation | 158.00K | 112.00K | 115.00K |
| CurrentDebt | 1.00M | ||
| OtherCurrentBorrowings | 1.00M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 642.00K | 207.00K | 253.00K |
| PayablesAndAccruedExpenses | 1.72M | 1.68M | 1.24M |
| CurrentAccruedExpenses | 788.00K | 1.36M | 999.00K |
| Payables | 929.00K | 319.00K | 240.00K |
| AccountsPayable | 929.00K | 319.00K | 240.00K |
| TotalAssets | 2.86M | 5.26M | 9.33M |
| TotalNonCurrentAssets | 613.00K | 277.00K | 494.00K |
| OtherNonCurrentAssets | 48.00K | 25.00K | 25.00K |
| NonCurrentPrepaidAssets | 5.00K | 5.00K | 5.00K |
| NetPPE | 560.00K | 247.00K | 464.00K |
| AccumulatedDepreciation | -69.00K | -87.00K | -239.00K |
| GrossPPE | 629.00K | 247.00K | 703.00K |
| Leases | 0.00 | 56.00K | 52.00K |
| OtherProperties | 530.00K | 247.00K | 582.00K |
| MachineryFurnitureEquipment | 99.00K | 77.00K | 69.00K |
| Properties | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 2.25M | 4.98M | 8.84M |
| OtherCurrentAssets | 62.00K | 24.00K | 42.00K |
| RestrictedCash | 35.00K | 25.00K | 25.00K |
| PrepaidAssets | 966.00K | 335.00K | 513.00K |
| CashCashEquivalentsAndShortTermInvestments | 1.19M | 4.59M | 8.26M |
| CashAndCashEquivalents | 1.19M | 4.59M | 8.26M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| FreeCashFlow | -8.42M | -4.54M | -3.38M |
| RepaymentOfDebt | -250.00K | 0.00 | |
| IssuanceOfCapitalStock | 3.05M | 522.00K | 2.75M |
| CapitalExpenditure | -22.00K | -12.00K | -40.00K |
| EndCashPosition | 1.27M | 4.64M | 8.31M |
| BeginningCashPosition | 4.64M | 8.31M | 10.08M |
| EffectOfExchangeRateChanges | -61.00K | -230.00K | -667.00K |
| ChangesInCash | -3.31M | -3.43M | -1.11M |
| FinancingCashFlow | 5.10M | 522.00K | 2.75M |
| CashFlowFromContinuingFinancingActivities | 5.10M | 522.00K | 2.75M |
| NetOtherFinancingCharges | 2.30M | ||
| ProceedsFromStockOptionExercised | 0.00 | 3.00K | |
| NetPreferredStockIssuance | 0.00 | 522.00K | 2.75M |
| PreferredStockIssuance | 0.00 | 522.00K | 2.75M |
| NetCommonStockIssuance | 3.05M | 0.00 | |
| CommonStockIssuance | 3.05M | 0.00 | |
| NetIssuancePaymentsOfDebt | -250.00K | 0.00 | |
| NetLongTermDebtIssuance | -250.00K | 0.00 | |
| LongTermDebtPayments | -250.00K | 0.00 | |
| InvestingCashFlow | -22.00K | 573.00K | -524.00K |
| CashFlowFromContinuingInvestingActivities | -22.00K | 573.00K | -524.00K |
| NetInvestmentPurchaseAndSale | 0.00 | 507.00K | -484.00K |
| SaleOfInvestment | 0.00 | 507.00K | 16.00K |
| PurchaseOfInvestment | 0.00 | -500.00K | |
| NetPPEPurchaseAndSale | -22.00K | 66.00K | -40.00K |
| SaleOfPPE | 0.00 | 78.00K | 0.00 |
| PurchaseOfPPE | -22.00K | -12.00K | -40.00K |
| OperatingCashFlow | -8.40M | -4.53M | -3.33M |
| CashFlowFromContinuingOperatingActivities | -8.40M | -4.53M | -3.33M |
| ChangeInWorkingCapital | -1.58M | 87.00K | 239.00K |
| ChangeInOtherWorkingCapital | 378.00K | -40.00K | -87.00K |
| ChangeInOtherCurrentAssets | -38.00K | 18.00K | |
| ChangeInPayablesAndAccruedExpense | -1.29M | 438.00K | -49.00K |
| ChangeInAccruedExpense | -1.90M | 359.00K | -11.00K |
| ChangeInPayable | 610.00K | 79.00K | -38.00K |
| ChangeInAccountPayable | 610.00K | 79.00K | -38.00K |
| ChangeInPrepaidAssets | -631.00K | -329.00K | 415.00K |
| ChangeInReceivables | 18.00K | -40.00K | |
| OtherNonCashItems | 3.80M | 318.00K | -268.00K |
| StockBasedCompensation | 5.86M | 130.00K | 125.00K |
| DepreciationAmortizationDepletion | 25.00K | 45.00K | 57.00K |
| DepreciationAndAmortization | 25.00K | 45.00K | 57.00K |
| Depreciation | 25.00K | 45.00K | 57.00K |
| OperatingGainsLosses | 16.00K | -1.00K | |
| GainLossOnSaleOfPPE | 16.00K | -1.00K | 0.00 |
| NetIncomeFromContinuingOperations | -16.52M | -5.11M | -3.49M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SLXN
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|